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Introduction
The beneﬁts of inhaled therapy for the treatment of
lung diseases have been recognised for many years.
In comparison with oral or parenteral formulations,
minute but therapeutic doses of drug are delivered
topically into the airways causing local effects within
the lung. Unwanted systemic effects are minimised as
the medication acts with maximum pulmonary spe-
ciﬁcity together with a rapid onset and duration of
action. Consequently, aerosol formulations of bron-
chodilators and corticosteroids are the mainstay of
modern treatment for asthma and chronic obstruct-
ive pulmonary disease (COPD). Central to the suc-
cess of inhaled treatment has been the availability of
efﬁcient aerosol delivery systems or ‘inhalers’. To
provide consistent clinical control, an appropriate
inhaler should satisfy the criteria that are described
in Figure 1.
The pressurised metered dose inhaler (pMDI) was
ﬁrst introduced 50 years ago for the delivery of bron-
chodilators (1). It was readily accepted by patients
and soon formulated to contain other classes of
asthma medications. It was particularly useful for the
administration of corticosteroids which hitherto had
been administered orally. Because of the large doses
needed for oral administration, corticosteroid treat-
ment for asthma was associated with an unacceptably
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SUMMARY
The use of dry powder inhalers (DPIs) to administer treatments for respiratory dis-
eases has increased signiﬁcantly in recent years. There is now a wide range of
DPIs available that vary considerably in design, required operational techniques,
output characteristics and drug delivery across a range of inhalation patterns. Dif-
ferent patient populations may ﬁnd individual types of DPI easier to use correctly
than others and selecting the right DPI for particular patient requirements will
improve compliance with therapy. For example, some DPIs offer a greater resist-
ance against inspirational ﬂow rate than others which affects the total emitted
dose and also ﬁne particle mass of the aerosol released. An individual patient may
therefore receive different amounts of drug when inhaling from different DPIs.
Therefore, it is important that the prescriber is fully aware of the characteristics of
the different types of DPI, so that he or she can prescribe the device that is most
appropriate to an individual patient’s needs. This review explores the characteris-
tics of currently available DPIs and evaluates their efﬁcacy and patient acceptabil-
ity. The differences in output characteristics, ease of use and patient preferences
between available devices is shown to affect treatment efﬁcacy and patient compli-
ance with therapy. Changing the DPI prescribed to a patient to a cheaper or gen-
eric device may therefore adversely affect disease control and thereby increase the
cost of treatment.
Review Criteria
The information presented in this review has been
sourced from published literature. In particular, the
review has focussed on comparative studies that
have measured in vitro aerosol output
characteristics of different types of dry powder
inhaler, and also clinical studies that have assessed
ease of handling and patient preferences for
different dry powder inhalers.
Message for the Clinic
Different types of dry powder inhaler have different
output and handling characteristics. Therefore, it is
important to select the best DPI for any given
patient, based on aerosol delivery, ease of handling
and patient preference because these factors
directly affect treatment compliance and therefore
disease control. Substituting a patient’s preferred
DPI for a cheaper, generic device may prove to be
a false economy and deleteriously inﬂuence
treatment efﬁcacy and patient outcomes.
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availability of inhaled formulations, with the intro-
duction of beclometasone dipropionate in 1972,
inhaled corticosteroids are now part of the corner-
stone of asthma treatment. Virtually every class of
inhaled drug is now formulated as a pMDI. This
small and unobtrusive device remains the most com-
monly used inhalation device worldwide (3), with
estimates of annual production in excess of 800 mil-
lion units (4). A signiﬁcant factor in its enduring
popularity is its advantage of being cheap and relat-
ively simple to manufacture on a large commercial
scale and also the availability of a range of drugs that
can be formulated for pMDIs.
In addition to pMDIs, dry powder inhalers (DPIs)
have been available since 1967. The Spinhaler
TM
(Aventis) was ﬁrst introduced for the delivery of
sodium cromoglycate (5). It was developed because
it was not possible for a pMDI to accommodate the
large (20 mg) required dose of sodium cromoglycate
for each administration. To deliver a dose of such
magnitude, this aerosol delivery system comprised an
inhaler which was supplied with separate capsules.
Each gelatin capsule contained a single dose of drug,
which was placed inside the inhaler before each use
and the empty capsule was discarded. Presentation of
the formulation in a capsule also provided protection
from moisture ingress. This is essential to maintain
good powder ﬂow and ensure that the drug particles
have the potential to be deposited in the lungs dur-
ing normal patient use. The Spinhaler
TM was regar-
ded as inconvenient to use because of the number of
steps required to administer each dose. Nevertheless,
this type of system is still widely used especially
when protection of the drug formulation from
moisture is important, for example the recent intro-
duction of tiotropium in the Handihaler
TM (Boeh-
ringer-Ingelheim) device.
A DPI has some distinct advantages over pMDIs
for the delivery of inhaled drugs to two particular
groups of patients. Many children and elderly
patients have difﬁculty using a pMDI correctly,
because of the high velocity at which each dose is
released and, therefore have problems following the
inhalation technique recommended in the Patient
Information Leaﬂet. Extensive training is required to
achieve correct use of a pMDI. To deliver the drug
effectively into the lung, the patient must actuate the
pMDI as they start to inhale. This requires a high
degree of ‘hand/lung’ co-ordination and failure to
achieve this often results in reduced effectiveness of
treatment and poor disease control (6,7). Because the
Spinhaler
TM required inspiratory effort to draw the
medication from the device, drug was only released
while the patient inhaled. Therefore, the issue of
‘hand-lung’ co-ordination was resolved. However,
this problem has been substituted by another prob-
lem that affects all DPIs. To ensure that the dose
emitted from a DPI contains drug particles that have
the greatest potential to be delivered to the conduct-
ing airways, it is necessary for the patient to generate
adequate inspiratory effort. The faster the inspiration
rate through the DPI (and hence acceleration), the
better is the quality of the emitted dose for lung
deposition. This applies to all DPIs, but for some the
effect is minimal, whereas other DPIs show signiﬁ-
cant ﬂow-dependent dose emission, which may result
in erratic dose emission and in turn compromise
consistent disease control. The latter problem could
be overcome by recommending adjustable mainten-
ance dosing regimens to a patient’s management
plan.
Concurrent with the introduction of DPIs was a
growing environmental concern that the chloroﬂu-
orocarbon propellants used in pMDIs were causing
irreparable damage to the ozone layer in the
atmosphere (8). The pharmaceutical industry was
therefore committed to the development of non-
chloroﬂuorocarbons (CFC) propellants for use in
pMDIs and also DPIs that required no propellant at
all. The reformulation to change the propellant used
in pMDIs to those based on hydroﬂuoroalkanes, in
place of CFC was not easy and some difﬁculties still
remain. Consequently, other DPIs began to appear
on the market. The ﬁrst such DPIs were similar to
the Spinhaler
TM, for example salbutamol (9) and
beclometasone dipropionate (10) delivered via the
Rotahaler
TM (GlaxoSmithKline) and ipratropium
bromide delivered by the Aerohaler
TM (Boehringer-
Ingelheim) (11). Dose emission from some of these
DPIs was less than that from the corresponding
pMDI and therefore the recommended doses from
the DPIs were double those from a pMDI.
Gradually, a new generation of novel DPIs became
available with extensively different designs, operating
characteristics and improved drug delivery to the lung.
Some devices contained a reservoir of drug such as the
Turbuhaler
TM (Astra Zeneca), Clickhaler
TM (Innovata
Biomed) and Easyhaler
TM (Orion), while other devices
had individually sealed unit doses of drug, such as
the Diskhaler
TM (GlaxoSmithKline) and Diskus
TM
(GlaxoSmithKline) (otherwise known as the Accuhaler
TM
in the UK). Some DPIs, such as the Clickhaler
TM and
Easyhaler
TM were designed to resemble pMDIs as clo-
sely as possible while other devices, such as Diskus
TM,
were designed to facilitate easy use and patient accep-
tability. Other reﬁnements such as integral dose coun-
ters to enable patients and their healthcarers to
monitor their inhaler use have also been incorporated
into the design of some DPIs. The importance of
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designed on the reservoir concept has also been
considered.
Dry powder inhalers have now an established role
in inhalation therapy. It is estimated that in 2004
approximately 113 million DPIs were dispensed
worldwide (12). As the number of different types of
DPIs on the market continues to increase, partic-
ularly with the advent of generic DPIs, the prescriber
may experience some uncertainty in the selection of
the optimal inhalation device for any given patient.
This may be compounded by recent suggestions that
because pMDIs are, in general, cheaper than DPIs,
they should be prescribed as ﬁrst-line treatments for
all patients (13,14). Furthermore, it has been pro-
posed that it is acceptable to switch patients from
more expensive DPIs to pMDIs or generic DPIs
without compromising treatment efﬁcacy in asthma-
tic patients (14). However, the interchangeability of
DPIs has been doubted (15).
Characteristics and performance
of dry powder inhalers
The range of DPIs that are currently available falls
into three device categories: single-unit dose inhalers
in which each dose is loaded into the device before
use; multi-dose reservoir inhalers in which a bulk
supply of drug is preloaded into the device and
multi-unit dose inhalers in which several single doses
are individually sealed and discharged each time the
device is actuated. Table 1 summarises the more
common DPIs that fall into the three categories. In
recent years, there has been a dramatic increase in
the number of patent applications for new DPIs and
it is anticipated that many more will be introduced
in the future. Furthermore, attention has recently
focussed on using the pulmonary route to deliver
active compounds into the systemic circulation. For
example, a DPI formulation of insulin (Exubera,
Pﬁzer in collaboration with Nektar Therapeutics) will
soon be available.
Single-unit dose devices
In single-unit dose devices, such as Spinhaler
TM,
Rotahaler
TM and Handihaler
TM, the drug, which is
formulated as a micronised powder in a lactose
excipient, is supplied in individual single-dose gelatin
capsules which must be inserted into the inhaler
before use. In the Spinhaler
TM, the capsule is placed
into a holder located on top of a propeller. The walls
of the capsule are pierced by two spears when the
patient primes the device by sliding a cam, while in
the Rotahaler
TM the capsule is severed by a twisting
action. Once the capsule has been broken, the patient
inhales through the device causing the propeller to
turn and vibrate dispersing the powder into the
inspired airstream (5,16). After use, the remains of
the gelatin capsule must be removed from the inhaler
before the next capsule can be placed in the device.
Consequently, devices such as these are inconvenient
to use and have largely been superseded by multi-
dose DPIs. However, a single-unit DPI, the Handi-
haler
TM, has recently been developed for the delivery
of tiotropium to patients with COPD (17). The use
of the Handihaler
TM has been shown to be associated
with a signiﬁcantly high and age-related error rate,
because of the complexity of its operation (18). In
addition, the Handihaler
TM has a high internal resist-
ance and many COPD patients have problems
achieving an adequate inhalation rate to emit the
required dose to be deposited in the airways (19,20).
As patients with COPD are generally older than asth-
matics, the use of simpler multi-unit dose DPIs,
which are easy to use and in which inhalation ﬂow
rate has minimal effect on dosage emission and ease,
such as Diskus
TM, may well be beneﬁcial in this pop-
ulation, (21,22) as well as those with asthma.
Multi-dose reservoir devices
Multi-dose DPIs, by deﬁnition, contain more than
one dose of drug. There are two types of multi-dose
DPI, reservoir and multi-unit dose devices. Multi-
dose reservoir devices contain a bulk supply of drug
from which individual doses are released with each
actuation. The ﬁrst such inhaler to be developed was
the Turbuhaler
TM (23) which is used to deliver
b2-agonists and corticosteroids separately and in
combination. The drug located within this inhaler is
formulated as a pellet of a soft aggregate of micron-
ised drug which may be formulated with or without
any additional lactose excipient. To release a dose of
drug, the patient twists the base of the device result-
ing in a dose of drug being shaved off the pellet
while holding the inhaler in a vertical position. It is
essential that this orientation is used when dose
metering all reservoir DPIs, because they rely on
gravity to ﬁll the dose metering cup. The dose is
then dispersed by turbulent airﬂow as the patient
inhales through the device. This turbulent airﬂow
creates the energy to disperse particles in the emitted
dose that are small enough to have a high possibility
of depositing in the conducting airways.
Other multi-dose reservoir devices have become
available in recent years including the Easyhaler
TM
(24), Clickhaler
TM (25) and Twisthaler
TM (Schering-
Plough) (26). The design of new multi-dose reservoir
DPIs has focussed on minimising the ﬂow-dependent
dose emission that occurs with the Turbuhaler
TM.
Also, attention has been directed to the protection of
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ine storage and patient use. For example, the Easy-
haler
TM has a protective case and the hopper is
designed, so that it is impossible for the patient to
blow into it. Furthermore, all multi-dose reservoir
DPIs are packaged with a protective wrapper to pre-
vent moisture ingress prior to dispensing and patient
use. The majority of this type of DPIs are disposable
and cannot be reﬁlled with additional drug. How-
ever, the Novolizer
TM (ASTA Medica) is rechargeable
and designed to be used with cartridges that contain
200 doses of drug (27).
Multi-unit dose devices
Multi-unit dose DPIs utilise individually prepared
and sealed doses of drug. The ﬁrst such DPI was the
Aerohaler
TM which contained six unit dose capsules
as a magazine, each delivering one dose of drug. The
device was used to deliver fenoterol and ipratropium
bromide and was very similar in design to single-unit
dose inhalers. The Diskhaler
TM is used in conjunc-
tion with reﬁll Rotadisks
TM which house four or
eight sealed blisters containing drug and lactose
excipient (28). Excipients such as lactose improve
dose uniformity by increasing the mass of powder
for each dose thereby improving the accuracy of dose
metering and minimising the effect of inhalation
ﬂow-dependent dose emission. The sealed blisters
offer a high degree of protection against environ-
mental factors such as humidity and because the pre-
metered doses of drug are factory prepared and
separately packaged, dose uniformity is assured. The
Table 1 Examples of commercially available dry powder inhaler
DPI type Device name Company Drugs available
Single-unit dose Aerolizer
TM Novartis Formoterol
Cyclohaler
TM Pharmachemie Salbutamol
BDP
Budesonide
Ipratropium bromide
Rotahaler
TM GlaxoSmithKline Salbutamol
BDP
Salbutamol + BDP
Spinhaler
TM Aventis Sodium cromoglycate
Inhalator
TM Boehringer-Ingelheim Fenoterol
Handihaler
TM Boehringer-Ingelheim Tiotropium
Multi-dose reservoir Clickhaler
TM Innovata Biomed/ML Labs Celltech Salbutamol
BDP
Easyhaler
TM Orion Pharma Salbutamol
BDP
Pulvinal
TM Chiesi Salbutamol
BDP
Turbuhaler
TM Astra Zeneca Salbutamol
Terbutaline
Formoterol
Budesonide
Formoterol/BUD
Twisthaler
TM Schering-Plough Mometasone
Novolizer
TM ASTA Medica Budesonide
Multi-unit dose Aerohaler
TM Boehringer-Ingelheim Ipratropium bromide
Fenoterol
Diskhaler
TM GlaxoSmithKline Salbutamol*
Salmeterol
BDP
FP
Diskus
TM/Accuhaler
TM GlaxoSmithKline Salbutamol
Salmeterol
FP
Salmeterol + FP
*Recently discontinued. BDP, beclometasone dipropionate; BUD, budesonide; FP, ﬂuticasone propionate.
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TM by lifting the
mouthpiece lid which causes a blister in the Rota-
disk
TM to be pierced and the dose to be released as
the patient inhales through the device. The Diskus
TM
or Accuhaler
TM, shown in Figure 2, was developed to
enable the sealed dose uniformity achieved in the
Diskhaler
TM to be combined with a larger number of
doses. Furthermore, the Diskus
TM was designed to
simplify use by providing up to 1 month’s medica-
tion in one device without the need to manually
replace spent cartridges or capsules. The Diskus
TM
houses a coiled strip of 60 double foil-wrapped indi-
vidual doses. The patient operates the inhaler by sli-
ding a lever which moves the next dose-containing
blister into place. A ratchet within the inhaler causes
the device to click when the next dose is properly
positioned. Priming the device in this way simulta-
neously peels the two layers of foil apart exposing
the dose ready for inhalation. The Diskus
TM also
incorporates a dose counter, which enables the
patient to monitor the number of doses remaining
in the device, and also has an integral outer case
which serves to keep the device dust free and also
resets the lever ready for the next dose.
Performance of DPIs
As a result of the wide variation in design character-
istics of the many DPIs available, their performance
characteristics vary considerably and this may impact
their suitability for use in different patient popula-
tions. Therefore, it is imperative that before prescri-
bing a DPI for an individual patient, the
characteristics of that DPI are known so that its
suitability can be assessed. The main factors des-
cribed in Figure 1 that must be taken into account
are summarised in Table 2.
Drug delivery
It is easy to assume that when an inhaler is actuated,
the dose of drug delivered to the patient is the same
as that cited on the package (label claim). However,
this is not always the case. There are considerable
differences in the proportions of the nominal dose
(label claim) released from different DPIs which is
deﬁned as the total emitted dose (TED). European
and American regulatory agencies have now put into
place standards that specify output requirements in
terms of the quantity and variability in the emitted
doses from DPIs (29,30). These standards are
designed to ensure consistent dosing from DPIs,
both throughout the life of an individual DPI and
also between inhalers of the same DPI make.
The TED is the term used to describe the quantity
of drug that is released from an inhaler during a sin-
gle actuation. Within the TED, therapeutic beneﬁt is
derived from the mass of drug particles that are
small enough to reach the airways during inhalation.
This parameter is described as the ﬁne particle frac-
tion (FPF) or ﬁne particle mass (FPM) and refers to
mass of particles released in an actuation that have
an aerodynamic diameter of < 5 lm (31). These par-
ticles have the greatest potential to be deposited on
to the airways during an inhalation. Larger aerosol
particles tend to deposit in the oropharynx and are
swallowed.
Both the TED and FPF are measured in the labor-
atory using in vitro pharmacopoeial methods. Using
Drug exit port
Manifold
Index wheel
Contracting
wheel
Body
Strip lid peeled from pockets Mouthpiece
Base wheel
Empty strip
Coiled strip Pockets
containing drug
Outer case
Cross section through device
Thumbgrip
Lever
Figure 2 The Diskus inhaler
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a wide variation in performance, in terms of TED
and FPF, from the range of DPIs available as a result
of intrinsic design differences. These design differ-
ences affect parameters such as the internal resistance
of a device which in turn affects the ﬂow rate
achieved through the DPI. For example, when the
Turbuhaler
TM and Diskus
TM were compared for the
delivery of budesonide and ﬂuticasone propionate
respectively, the Diskus
TM delivered 87–93% of the
label claimed dose while the Turbuhaler
TM delivered
40–58% (32).
Flow rate has been shown to directly affect the pro-
portion of the nominal dose (TED) and also the FPF
of the aerosol released from different types of DPI.
This effect is more signiﬁcant with some DPIs than
others. For example, at a constant sampling ﬂow rate
(60 l/min), the FPF varied by 40% of the nominal
dose in the Turbuhaler
TM and < 10% with the Spin-
haler
TM (33). Furthermore, even within a particular
type of DPI, ﬂow rate directly affects both TED and
FPF. For example, increasing the ﬂow rate of air
through a budesonide/formoterol Turbuhaler
TM from
30 to 60 l/min and 90 l/min resulted in increases in
the budesonide TED from 37.5% to 64.4% and
107.4% respectively (34), with similar increases in
formoterol TED, as shown in Figure 3. Increases in
FPM were also observed in parallel with ﬂow rate.
Similarly, the FPM of both drugs more than doubled
when the ﬂow rate was increased from 30 to 60 l/
min. Figure 3 also highlights that intra-inhaler dose
emission can also be erratic. However, this phenom-
enon was not found for the Easyhaler
TM or the Disk-
us
TM when studied at different ﬂow rates (35) as
shown in Figure 4. Large intra- and interinhaler dose
emission differences could have clinical consequences
in the bronchodilator treatment of asthma exacerba-
tions. Also, because of the absence of immediate
therapeutic feedback when inhaling corticosteroids,
these differences may also cause problems in achiev-
ing adequate asthma or COPD control. Therefore, it
is important that a DPI should deliver a consistent
dose irrespective of a patient’s inspiratory ﬂow rate.
The rationale for the presentation of drug as indi-
vidually, factory-measured unit doses as supplied in
Table 2 Factors affecting dry powder inhaler use
Drug delivery Consistent dose delivery throughout device life
Dose reproducibility across range of temperatures and humidities
High proportion of dose available for inhalation over a range of inspiratory ﬂow rates
Large ﬁne particle mass in relation to total emitted dose (see section Drug delivery)
Low resistance of device to airﬂow during inhalation
Ease of use Small number of steps required to actuate device
Low inhaler technique training requirements
Low degree of manual dexterity required to use device
Patient preference Appropriate size and low obtrusiveness
Incorporation of a dose counter
Positive reinforcement of dose delivery
30                  60                      90
Flow rate (l/min)
Flow rate (l/min)
Formoterol
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Figure 3 The amounts of budesonide and formoterol
(expressed as a percentage of the labelled emitted dose)
emitted from each dose of the six inhalers tested using
in vitro inhalation ﬂow rates of 30, 60 and 90 l/min
(reproduced with permission)
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TM was to ensure a higher degree of dose
consistency throughout the life of the device than
that achieved in multi-dose reservoir devices (36).
Consistent dosing from the Diskus
TM has been found
with salmeterol (37), ﬂuticasone propionate (38) and
the combination of both salmeterol and ﬂuticasone
propionate (39) and is therefore independent of the
drug delivered. Figure 4 illustrates the minimal effect
of inhalation ﬂow rate on the dose emitted from the
Diskus
TM. Furthermore, multi-unit dose inhalers,
such as Diskus
TM have been shown to deliver more
consistent doses across a wide range of sampling ﬂow
rates than the Turbuhaler
TM reservoir multi-dose
device (40,41,32).
In vitro techniques such as those described above
provide valuable data that gives an indication of
where an aerosol may deposit in the airways (42).
However, FPF measured under laboratory condi-
tions cannot be extrapolated into a direct measure
of drug deposition (43). For example, most inertial
impaction devices, such as cascade impactors des-
cribed in the pharmacopoeial methods, sample aero-
sol from an inhaler by drawing air through the
device at a constant sampling ﬂow rate (usually
60 l/min, or the ﬂow rate achieved at a pressure
drop of 4 KPa). This is not representative of in vivo
use. In practice, the magnitude of airﬂow passing
through the DPI during use is variable and con-
trolled by the patient’s ability to inhale. An indivi-
dual patient’s inspiratory capacity is affected by
several parameters including lung size, degree of air-
way obstruction that is present and their inspiratory
musculature. In addition to these patient factors,
the resistance of the inhaler itself affects the ﬂow
rate a patient can achieve when inhaling through
the device. Each type of DPI has its own resistance
characteristics which are caused by the internal
structure of the device and there is considerable
variation in this parameter between available DPIs
(44). The higher the internal resistance of a DPI,
the lower the ﬂow rate a patient can generate dur-
ing inhalation at a given inspiratory pressure.
A modiﬁcation of the aerosol sampling methodo-
logy used to obtain the TED and FPF measurements
at variable ﬂow rates has been developed. This tech-
nique, using the Electronic Lung, employs a variable
sampling ﬂow rate which is derived from in vivo
recordings of patient breathing patterns. This ex vivo
technique enables inhalation proﬁles from different
patient groups to be recorded using a pressure-sensi-
tive device. The recorded proﬁles are replayed via an
electronic synthesiser which exactly copies the
patient’s inspiration through a sampling device while
the aerosol is released from the DPI. Using this tech-
nique to simulate the breathing pattern of asthmatic
children aged 4–8 years, the TED of ﬂuticasone
propionate via the Diskus
TM was compared with that
of budesonide delivered via the Turbuhaler
TM (45).
The results for TED were in general agreement with
those obtained by pharmacopoeial methods and
showed that 87–89% of the label claim was emitted
from the Diskus
TM compared with 56–62% from the
Turbuhaler
TM. However, while the TED from the
Diskus
TM was greater than that from the Turbuhal-
er
TM, the FPF from the Diskus
TM was slightly lower
than that from the Turbuhaler
TM (15–18% compared
with 21–32% respectively). Overall, the results
showed that Diskus
TM delivered a more consistent
dose across the varying inhalation patterns than the
Turbuhaler
TM (45).
0%
20%
40%
60%
80%
100%
120%
140%
160%
30 l/min 30 l/min 30 l/min 40 l/min 60 l/min 60 l/min 60 l/min 90 l/min
Diskus Turbuhaler Easyhaler
Palander et al Clin Drug Invest 2000;20:25-33
Figure 4 Uniformity of dose delivery from three salbutamol-containing multi-dose powder inhalers. Buventol Easyhaler
 
(200 lg/dose), Inspiryl Turbuhaler
  (100 lg/dose) and Ventolin Diskus
  (200 lg/dose) at different ﬂow rates. The
delivered dose is expressed as a percentage of the nominal labelled dose. Each data point represents a single-dose actuation
(reproduced with permission)
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the dose that severe asthmatics would receive when
inhaling from a Diskus
TM (containing 500 mcg ﬂuti-
casone propionate with 50 mcg salmeterol) and a
Turbuhaler
TM (containing 200 mcg budesonide and
6 mcg formoterol) (46). Figure 5 illustrates the range
of inspiratory ﬂow rates generated by the patients
through the two devices and shows that while that
the effect of inhalation ﬂow rate on the dose emitted
from the Diskus was minimal, it had a signiﬁcant
effect on that released from the Turbuhaler
TM. Fig-
ure 6 illustrates that there was an inverse relationship
between inspiratory ﬂow rate and mass median aero-
dynamic diameter (MMAD) of aerosol released from
both DPIs. The change in the MMAD with inhala-
tion ﬂow rate was similar for both devices (46). This
decrease in MMAD would counteract the greater
potential for more central deposition of particles
when using a faster inhalation ﬂow rate.
Most DPIs are designed to be used by a spectrum
of patients from children to the elderly people with a
wide range of severities of asthma symptoms. This
variety of patients inherently has different inhalation
capacities and therefore generates varying inspiratory
ﬂow rates. As small children have smaller inspiratory
capacities than adults in terms of both ﬂow rate and
volume, DPIs are generally not advocated for chil-
dren under the age of 6 years. However, Diskus
TM
operates at low ﬂow rates and has been shown to be
effective for use in children aged as young as 4 years
(47). The TED and FPF released by some DPIs have
been shown to vary considerably and be affected by
differences in inspiratory ﬂow rate (48,33,44). A
study conducted to compare the delivery of Sere-
tide
TM via the Diskus
TM inhaler with that of Symbi-
cort
TM via the Turbuhaler
TM showed that while the
output from the Diskus
TM was consistent across a
range of ﬂow rates, the output from the Turbuhal-
er
TM varied considerably across the same range.
Therefore, delivery from the Turbuhaler
TM was
directly affected by the inspiratory ﬂow rate of the
patient (49). Similarly, the FPF of formoterol deliv-
ered via Turbuhaler
TM was found to be more
dependent on inspiratory ﬂow rate than that of
salmeterol delivered via Diskus
TM (41). A study was
conducted to measure the ability of asthmatic chil-
dren and older COPD patients to generate adequate
inspiratory ﬂow through three different DPIs [Disk-
us
TM, Turbuhaler
TM and Aerolizer
TM (Novartis)].
The results showed that all patients could generate
adequate ﬂow through the Diskus
TM. However, only
57% could generate adequate ﬂow through the Tur-
buhaler
TM and 21% through the Aerolizer
TM (50). A
further study in children highlighted the problems
that some may have to generate sufﬁcient inspiratory
effort to receive the required dose from a Turbu-
haler
TM and recommended that this device should
not be prescribed to preschool age children (51).
The use of radio-labelled medications allows the
in vivo deposition of the aerosol to be observed and
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Figure 5 Mean (± SD) inhalation ﬂow proﬁle from the 20
severe asthmatics when they used a Diskus
  ( ) and
Turbuhaler
  ( ) (reproduced with permission)
Figure 6 The mass median aerodynamic diameter with a peak inhalation ﬂow (A) budesonide and ﬂuticasone propionate
and (B) formoterol and salmeterol (the continuous line represents the line of regression for ﬂuticasone and salmeterol, the
dashed line for budesonide and formoterol) (reproduced with permission). FP, ﬂuticosone propionate
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Using such methodologies, it has been possible to
compare the lung delivery of inhaled medications
delivered via different inhalers. For example, mean
total lung deposition of 99 mTc-labelled salbutamol
was calculated at 18% when delivered from a pMDI
and 11% from a Diskhaler
TM in asthmatic patients
(52). Predictably, lung deposition was found to be
higher in normal subjects without airﬂow obstruc-
tion, as illustrated by the study of Borgstro ¨m et al.
(53) who showed 27% and 28% lung deposition of
99 mTc-labelled terbutaline and budesonide respect-
ively via the Turbuhaler
TM when inhaled at approxi-
mately 60 l/min. However, this study also showed
that lung deposition from the Turbuhaler
TM was
highly dependent on inspiratory ﬂow rate and was
halved to approximately 15% when the subject
inhaled at 36 l/min. These in vivo studies highlight
the in vitro and ex vivo results thereby showing the
value of these laboratory methods to predict in vivo
effects.
Just as tablet formulations of medications are sub-
ject to pharmaceutical deterioration when exposed to
excessively high temperatures and humidity, the
pharmaceutical performance of inhalers may also be
adversely affected. The manufacturers of Diskus
TM
and Turbuhaler
TM recommend in their Summary of
Product Characteristics for Seretide
TM and Symbi-
cort
TM respectively that they should not be stored at
temperatures above 30  C. Regulatory agencies
require that inhalers should be tested for pharmaceu-
tical stability over the long term (3 months) at 25  C
and 60% relative humidity (RH) and should also
show short-term (1 month) stability at 40  C and
75% RH.
Conditions of high temperature and humidity
have been shown in in vitro studies to negatively
affect the efﬁcacy of the Turbuhaler
TM plastic reser-
voir device (54). The effect of hot and humid storage
conditions on the FPF from the terbutaline Turbu-
haler
TM has been studied in vitro. It was found that
there was considerable variation in output from the
Turbuhaler
TM over the range of test conditions and
FPM was reduced to near zero when it was used at
5  C (55). The Turbuhaler
TM has been equipped
with a detachable cap that forms a seal on the outlet
of the inhaler when it is closed properly. This, of
course, relies on the co-operation of the patient to
put the lid ﬁrmly back on to the device after each
use. In the Diskus
TM, each dose of drug is protected
from the environment by moisture proof, sealed alu-
minium foil units, which are peeled back to expose
each dose just as it is used. This has been shown to
provide a high level of dose protection (37). In addi-
tion to the foil strip, the Diskus
TM is also supplied
with an outer foil wrapper which provides extra pro-
tection from the environment during storage prior to
use. A recent study showed that the FPF (but not
TED) from the Diskus
TM was shown to be reduced
by 50% after 3 months of storage at high tempera-
ture and humidity (40  C/75% RH), while that from
the Turbuhaler
TM was not affected to the same
extent (56). However, in this study Diskus
TM inhalers
were used that had limited unexpired shelf life and
no assurance was given regarding the storage condi-
tions of these inhalers prior to their use in this study.
Furthermore, the conditions of temperature and
humidity under which the aerosol was sampled from
the inhalers differed considerably from the condi-
tions under which the inhalers had been stored. It is,
therefore, difﬁcult to assess whether the observed
changes in FPM were due to the experimental condi-
tions, ambient conditions during sampling or previ-
ous storage conditions of the inhalers.
Ease of use
Arguably, the most important criterion in the selec-
tion of a DPI is its ease of use. Even if a DPI is
shown to have an excellent pharmaceutical perform-
ance in terms of drug output, if it is not used cor-
rectly then it can be rendered ineffective. The results
of a recent survey conducted in 169 patients with
asthma or COPD showed that patients rated ‘ease of
use during an attack’ as the most important feature
of an ideal inhaler (57). If patients cannot use an
inhaler correctly, their treatment is compromised
which may have extremely serious consequences.
Dry powder inhaler devices have an inherent
advantage over pMDIs, because the dose of drug is
only released from the inhaler as the patient inhales.
Therefore, it is not necessary for the patient to co-
ordinate inspiration with actuation of the device.
However, it is still necessary for the patient to provide
a sustained inspiration of adequate ﬂow rate through
the inhaler in order for the complete dose to be
released. The inspiratory ﬂow rate required for opti-
mum delivery depends on the individual DPI and the
ease with which a patient can generate this ﬂow rate
depends on the resistance of the individual DPI.
The diverse characteristics of patients who require
inhaled medications are such that simplicity of
operation is of paramount importance. One study
assessed patients’ use of their own DPI or pMDI and
found that nearly 90% made at least one mistake in
their inhalation technique (58). It is therefore imper-
ative to provide training to patients so that they
learn to use their DPIs correctly. It has been shown
that effective training increases patients’ ability to
use a DPI correctly (57,59). Table 3 summarises the
instructions for use of some popular DPIs (60).
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instruction, 74% patients were able to use the Disk-
us
TM correctly compared with only 32% patients
who were able to use the Turbuhaler
TM correctly
after one instruction (61). After two training ses-
sions, 99% patients could use the Diskus
TM correctly
and 88% patients used the Turbuhaler
TM correctly.
However, 12% of the patients studied required
further training before they could operate the
Turbuhaler
TM.
Many studies have highlighted the incorrect use of
inhalers and have shown that some inhalers are eas-
ier to use than others. However, many such clinical
studies require patients to have a good inhalation
technique as an inclusion criterion. Therefore, real-
life studies such as observational studies may be
more relevant in evaluating DPI use. For example,
an observational study in 3811 patients compared
correct use of ﬁve types of inhaler (Aerolizer
TM,
Autohaler
TM, Diskus
TM, Turbuhaler
TM and MDI)
(62). There were clear differences between devices in
the percentage of patients who made at least one
mistake during use. Fewer patients made a mistake
when using the Diskus
TM compared with the other
devices. The percentage of patients who made errors
that would result in ineffective dosing was also low-
est when they used the Diskus
TM (11%) and highest
during use of the Turbuhaler
TM (32%). Similar ﬁg-
ures of incorrect use of the Turbuhaler
TM have been
found in other studies in adults and also in children
(59,63–67). A study conducted in elderly patients
with COPD demonstrated that patients made signiﬁ-
cantly fewer critical errors when they used the Disk-
us
TM inhaler than when they used the single-unit
dose Handihaler
TM inhaler (22). DPIs may also be
used to deliver other medications such as antiviral
drugs to elderly patients who have not used any
inhalers before. A study conducted to determine
whether elderly people could use Relenza
TM Diskhal-
er
TM as effectively as Turbuhaler
TM found that 74%
of patients had difﬁculty to load and prime the Disk-
haler
TM compared with 43% of patients with difﬁ-
culty using the Turbuhaler
TM (68). Clearly, it is
important to maximise simplicity of use for elderly
patients who are unfamiliar with inhaled therapy.
The design of a DPI is critical in facilitating cor-
rect use. It should be easy to hold by all patients
including the elderly people who may have concom-
itant conditions such as arthritis that can affect man-
ual dexterity. Similarly, a DPI should be easy to
operate with a minimal number of required steps.
The mouthpiece should be designed to be comfort-
able during use. Furthermore, the device should offer
minimal resistance to airﬂow so that it is easy for
the patient to inhale through the device. Some DPIs
(e.g. Clickhaler
TM, Easyhaler
TM) have been designed
to resemble pMDIs as closely as possible, in terms of
size and unobtrusiveness. However, because the
mode of operation of a DPI is so different from that
of a pMDI, swapping a patient from a pMDI to such
a DPI may cause confusion to the patient and result
in incorrect use.
Several clinical studies have shown that the Disk-
us
TM is easier to use than the Turbuhaler
TM in
elderly people, adult and paediatric patients (69–75).
Similarly, the Diskus
TM has been found to be easier
to use than the Diskhaler
TM (76,77).
Patient preference
Patient preference has been identiﬁed as the second
most important consideration for device selection
after ease of use (78). The recognition that patients
have distinct personal preferences regarding the
inhaler that they use and are able to make
informed choices is particularly important in estab-
lishing an effective disease management partnership
between the healthcare professional and the patient.
Compliance with the treatment is improved when
patient and physician work together to achieve
effective disease control (79). Many studies have
been conducted to establish patient preference for
one device over others. The results show that there
is enormous variation in preferred devices. Table 4
summarises the ﬁndings of some of the studies in
which patient preference for one DPI over another
was compared.
Table 3 Instructions for dry powder inhaler use from Patient Information Leaﬂets (60)
Device Loading dose Preparation for inhaling the dose Inhaling dose
Clickhaler
TM Hold upright, shake, press Breathe out as far as comfortable Steadily and deeply
Diskhaler
TM Insert disk, slide tray, pierce disk Breathe out as far as comfortable Suck in quickly and deeply
Diskus
TM Open, slide Breathe out as far as comfortable Suck in quickly and deeply
Easyhaler
TM Hold upright, shake, press Breathe out Strongly and deeply
Pulvinal
TM Hold upright, press button, twist Breathe out deeply As quickly and deeply as possible
Turbuhaler
TM Hold upright, twist base Breathe out gently Deeply and as hard as possible
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designed to show overall preference for one device
over another, in reality patients may prefer certain
features of one inhaler over those of another inha-
ler, but not necessarily other features. Therefore,
studies have been conducted to identify the most
important characteristics or features of an ‘ideal’
DPI for different groups of patient (80–83). The
ﬁndings of these studies show that different groups
of patients or parents have different priorities. For
example, parents of children who administer the
dose of medication to their child rated that it was
more important to them to feel that the child had
received the dose than it was for children or adults
who self-administer the medication (83). Similarly,
children stated that they preferred a small device
that was easy to carry around, while this character-
istic was not as important to adults or parents,
and elderly patients may well wish for a larger
device that is easier to see and hold. Clearly, dif-
ferent patient populations have different priorities
and ‘wish lists’ for an ideal inhaler. A recent study
set out to identify the ‘wish list’ among 250
patients with COPD (21). The three most import-
ant features of an ideal inhaler were being quick
to use when needed, overall ease of use and having
a counter to show how many doses remained in
the device. The study found that the Diskus
TM was
rated signiﬁcantly higher than the Handihaler
TM
for each of these features.
Interchangeability of DPI devices
The ﬁndings of some studies have suggested that
clinical equivalence can be achieved when generic
inhalers are substituted for other DPIs (84). How-
ever, such studies do not accurately reﬂect real-life
situations and the effectiveness of inhaled medication
to achieve disease control is the result of a combina-
tion of device design, pharmaceutical performance
and patient behaviour.
The ﬁndings of this review have shown that there
are wide differences between currently available DPIs
in terms of pharmaceutical performance, ease of use
and patient preference. It is clear that ‘one inhaler
does not ﬁt all’ and several factors should be taken
into consideration when prescribing a dry powder
inhaler device. However, two recent reviews have
compared the clinical effectiveness of pMDIs with
DPIs in the delivery of bronchodilators and cortico-
steroids in asthma (13,14). The conclusion of each
review was that ‘no evidence was found that alternat-
ive inhaler devices (DPIs, breath-actuated pMDI) are
more effective than the pMDI for the delivery of
b2-agonist or corticosteroids in asthma. pMDI
remain the most cost-effective delivery devices’. In
Table 4 Summary of studies to identify patient preference for dry powder inhalers
Comparisons Comments References
BDP Easyhaler
TM vs. Diskhaler
TM N ¼ 185. Easyhaler
TM rated more acceptable
than Diskhaler
TM
Wettengel et al. (84)
Salmeterol or FP Diskus
TM vs. Diskhaler
TM Diskus
TM preferred to Diskhaler
TM Boulet et al. (77)
Stallaert et al. (97)
Diskus
TM vs. previous device Diskus
TM preferred to previous device (53% vs.
Turbuhaler
TM; 82% vs. Diskhaler
TM; 83% vs.
Rotahaler
TM; 92% vs. Spinhaler
TM)
Le Soeuf and Clay (98)
Diskus
TM vs. Easyhaler
TM vs. Turbuhaler
TM Adult stable asthmatics scored Easyhaler
TM 75
(of 90); Diskus
TM 67 and Turbuhaler
TM 65
Giner et al. (83)
Diskus
TM vs. Handihaler
TM 67% COPD patients preferred Diskus
TM Moore and Stone (21)
Diskus
TM vs. Turbuhaler
TM More patients prefer Diskus
TM (60–82%) to
Turbuhaler
TM (8–18%). Turbuhaler
TM preferred
in one study (50% vs. 34%)
Luyt et al. (74)
Arossa et al. (71)
Chapman et al. (72)
Serra-Batlles et al. (57)
Manjra et al. (99)
van der Palen et al. (75)
Willingness to use Diskus
TM vs. Turbuhaler
TM More patients happy to be prescribed Diskus
TM
again (78–91%) than Turbuhaler
TM (37–65%)
Backman et al. (70)
Williams and Richard (100)
Chapman et al. (72)
Burdon et al. (73)
COPD, chronic obstructive pulmonary disease.
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prising. This is because both reviews concentrated on
the results of clinical studies in which patients were
selected whose asthma symptoms were stable, and
who demonstrated a good inhaler technique and
were compliant with the dosing regimen of the
study. Furthermore, the treatment periods in many
of the studies cited were of short duration and
because many of the studies were designed to show
equivalence, doses were selected that were at the top
of the dose–response curve. Consequently, many of
the studies cited in these reviews demonstrated clin-
ical equivalence between a standard pMDI and the
alternative inhaler device.
The proportion of a dose of medication from a
DPI that deposits in the lung during inhalation var-
ies as a result of the device used, the drug delivered
and the patient characteristics (85). A study was con-
ducted in healthy volunteers that compared the lung
deposition of
99 mTc radio-labelled budesonide when
delivered via Clickhaler
TM and Turbuhaler
TM. Lung
deposition was assessed by the use of scintigraphy.
The results showed that delivery of the budesonide
to the lungs was directly affected by the device used
and was signiﬁcantly lower from the Turbuhaler
TM
(15.8%) compared with the Clickhaler
TM (26.8%)
(p < 0.001) (86). Similar ﬁndings were obtained
when the deposition of sodium cromoglycate was
compared from four different DPIs (87). Such differ-
ences in deposition have been shown to affect the
safety proﬁles of inhaled corticosteroids. For exam-
ple, in a 6-month study of children aged 5–10 years,
delivery of budesonide via Turbuhaler
TM was found
to cause a signiﬁcantly slower growth rate in these
children than when the same drug was delivered via
Easyhaler
TM (88). Therefore, the pharmaceutical per-
formance of a DPI, and consequent systemic absorp-
tion of the drug, has been shown to directly affect
the safety proﬁle of an inhaled medication. Similar
differences in systemic absorption have been found
when salbutamol was delivered from Diskus
TM, Tur-
buhaler
TM, Easi-breathe
TM and Diskhaler
TM (89).
This therefore indicates that changing a delivery
device can have adverse effects on both the safety
and efﬁcacy of an inhaled drug and that DPIs should
not be regarded as interchangeable (15).
It is recognised that patient factors such as ease of
use and patient preference directly affect treatment
compliance. Therefore, if patients are switched from
devices that they ﬁnd simple to operate and like to
use, then compliance with therapy may well deterior-
ate. This, in turn, will result in a loss of symptom
control and consequent increases in morbidity and
also healthcare costs. Furthermore, substitution of a
familiar inhaler with a generic inhaler could confuse
the patient causing them to make additional
appointments to see their doctor or nurse thereby
negating any possible cost savings.
The availability of a DPI that can be used to deli-
ver a range of drugs is important as patients become
used to using a particular device effectively. The
Diskus
TM is available with salmeterol, ﬂuticasone
propionate and also the combination of both drugs
at three different strengths. Analysis of prescribing
habits, by managed care organisations in the USA,
has shown that reﬁll rates are higher when patients
are prescribed combination inhalers compared with
two separate inhalers each containing a single agent
(90). Improving compliance with therapy regimens
results in less reliever use, lower exacerbation rates
and reduces the overall healthcare costs of respiratory
disease (91).
Conclusions
National and international guidelines state that the
aim of asthma management is to achieve optimal
disease control (92–94). Poorly controlled asthma
results in increased exacerbations of symptoms and
resultant healthcare costs (95) and also negatively
impacts quality of life (96). Poorly controlled COPD
also results in an increased rate of disease progres-
sion, exacerbations requiring hospitalisation and ulti-
mately mortality. Fundamental to achieving optimal
disease control in both asthma and COPD is the
provision of effective and reliable treatment. DPIs
have become popular for the delivery of inhaled
medications for both asthma and COPD. Improve-
ments in technology and pharmaceutical science have
facilitated the development of DPIs that are simple
to use, provide consistent dosing of drug and are
liked by patients. However, there are still wide varia-
tions in these properties among the different makes
of DPI available. The prescriber must therefore
ensure that the selection of a delivery device is
appropriate for the individual patient needs. While it
has been suggested that it is acceptable to swap a
patient to the cheapest device available without com-
promising disease control, this is not supported by
the clinical evidence that clearly demonstrates that
there are wide differences between the quality of
treatment delivered by different DPIs. The ‘ideal’ dry
powder inhaler is the one that delivers consistent
and reliable doses and is the one that the patient
trusts, ﬁnds easy to use and prefers over others.
While there is no single ‘ideal’ DPI that fulﬁls all
those criteria for the entire spectrum of patients
who use inhaled medications, the evidence suggests
that multi-unit dose DPIs such as Diskus
TM offer
the most reliable and consistent pharmaceutical
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them as the easiest to use.
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